Our results may inform clinical decisions regarding personalized therapeutic modulation of EGFR/ERK and Notch signalling pathways in this high‐risk population and reveal the potential utility of ADAM17 inhibition in treating patients with EC and more broadly patients with other FGFR2‐dependent tumours. This evidence concerns the gene EGFR and neoplasm.